02.21.23 -- Facilitating More Efficient Advanced Therapy Production

Bioprocess manufacturing is increasingly important in healthcare and other fields. Earning the necessary approvals for research processes to transition from R&D to manufacturing is raising new challenges. Explore some factors to consider when making the critical decision on whether to use an open or closed system for the manufacturing process.

As the allogeneic cell therapy industry moves beyond proof of principle experimentation and toward more human clinical trials, sponsors have a mighty challenge ahead of them: growing more cells. Look into the details of some automated scale-up solutions and how you can design and execute your allogeneic cell therapy seed chain from Phase 1 onward.

Success in gene therapy relies upon the safe, precise delivery of genetic payloads to the intended target cells. Explore a novel approach that combines next-gen library synthesis, next-gen sequencing, AI, and novel fixed-bed bioreactor technology to accelerate the production of improved indication-specific AAV capsids to deliver therapeutic transgenes.

Is your company interested in a new type of biomedicine that allows therapies and treatments to be personalized to meet individual patients’ needs? Speakers from leading institutions and organizations working with Precision Medicine came together to discuss what effective models they are using for current research and the future applications and promise in this space.

Maintaining culture in adherent conditions at scale is possible with forethought into workflow integrations, automation, and platform choices in developing a manufacture-ready seed train for these powerful cultures. We explore what researchers should consider when they are creating a risk-mitigating adherent culture process for cell and gene therapy scale-up.